Financial Data and Key Metrics Changes - In 2025, WuXi AppTec achieved total revenue of RMB 45.46 billion, with revenue from continuing operations growing 21.4% year-over-year to RMB 43.42 billion [6] - Adjusted non-IFRS net profit grew 41.3% year-over-year to RMB 14.96 billion, with a non-IFRS net profit margin improving 5.9 percentage points to 32.9% [6][20] - Adjusted non-IFRS gross profit reached RMB 21.89 billion, with a gross profit margin expanding to 48.2%, up 6.6 percentage points year-over-year [20] Business Line Data and Key Metrics Changes - WuXi Chemistry revenue grew 25.5% year-over-year to RMB 36.47 billion, with an adjusted non-IFRS gross profit margin of 52.3% [11] - Small molecule D&M business revenue increased 11.4% year-over-year to RMB 19.92 billion [12] - TIDES revenue almost doubled to RMB 11.37 billion in 2025, with a backlog growth of 20.2% year-over-year [15] Market Data and Key Metrics Changes - Revenue from the U.S. market grew 34.3% year-over-year, while Japan, Korea, and other regions grew 4.1% [8] - Europe and China experienced declines mainly due to fluctuations in project delivery timing [8] Company Strategy and Development Direction - The company remains focused on enhancing core capabilities and capacity to meet customer demand, with a strong emphasis on the CRDMO business model [7][23] - WuXi AppTec aims to drive operational efficiency and resilience to navigate dynamic market conditions, with a revenue guidance of RMB 51.3 billion to RMB 53 billion for 2026 [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining rapid business growth despite macroeconomic uncertainties, with a continuing operations revenue growth expectation of 18%-22% for 2026 [28][60] - The company is closely monitoring geopolitical situations and their potential impacts on operations and costs, maintaining a mature and diversified procurement network [31][59] Other Important Information - WuXi AppTec achieved MSCI AAA and CDP Climate Change A ratings in 2025, reflecting its commitment to sustainability [9] - The board proposed a cash dividend distribution plan totaling RMB 5.7 billion in 2026, maintaining a 30% annual cash dividend payout ratio [25] Q&A Session Summary Question: Impact of currency exchange on guidance - Management acknowledged the impact of FX movements but expressed confidence in their execution capabilities and the visibility provided by the CRDMO business model [30] Question: Geopolitical impact on margins - Management noted potential risks to upstream raw material costs but emphasized their operational efficiency and procurement strategies to mitigate impacts [31] Question: Pipeline behind TIDES CapEx budget - Management highlighted the ongoing demand for peptides and the growth potential of oligonucleotides, indicating a focus on multiple modalities [32][33] Question: Client outsourcing strategy changes - Management stated that large pharma's internal manufacturing does not change their commitment to improving capabilities and providing services [35] Question: Current utilization rate of small molecule capacity - Management indicated strong demand and ongoing collaborations with leading companies, enhancing their business in the Biology and Testing sectors [37] Question: Impact of FDA's regulatory changes on drug approvals - Management expressed that any regulatory streamlining would benefit patients and potentially increase demand for drug substances [39] Question: Positioning in oral small molecule GLP-1 CDMO business - Management confirmed strong growth in the small molecule sector, particularly in GLP-1 drugs, and anticipated benefiting from high demand [41][46] Question: Revenue breakdown and geographical mix - Management noted strong growth across all regions, with expectations for continued growth in the U.S., China, and Europe [48][52] Question: Sustainability of TIDES business growth - Management expressed confidence in sustained growth driven by a robust pipeline and ongoing demand for their products [54] Question: Timeline for new facility contributions - Management stated that new facilities in China can become operational in less than 12 months [57] Question: Competitive landscape in siRNA CRO space - Management acknowledged the presence of many players but emphasized their focus on quality, speed, and cost as competitive advantages [62][64] Question: Confidence in new orders and booking assumptions - Management expressed confidence in converting backlog into revenue and maintaining strong execution capabilities [66]

Summary of WuXi AppTec FY Conference Call Company Overview - **Company**: WuXi AppTec (SEHK:02359) - **Industry**: Healthcare, specifically in the biopharmaceutical sector - **Conference Date**: January 14, 2026 Key Highlights - **Financial Performance**: - Preliminary estimates for 2025 indicate total revenue of **45.5 billion RMB**, a **21.4%** year-over-year growth in continuing operations [5] - Adjusted non-IFRS net profit reached **15 billion RMB**, with a net profit margin of **32.9%**, reflecting a **5.9 percentage point** improvement year over year [5][12] - Backlog exceeds **55 billion RMB**, positioning the company for sustainable future growth [5] - **CRDMO Model**: - WuXi AppTec operates an integrated CRDMO (Contract Research, Development, and Manufacturing Organization) platform, supporting every stage of drug R&D from discovery to commercial manufacturing [4][17] - The company has expanded its total reactor volume for small molecule APIs to over **4 million liters** and solid phase peptide synthesizer capacity to over **100,000 liters** [4] - **Customer Engagement**: - The company has collaborated with nearly **6,000 partners** across more than **30 countries** [4] - Supported **21%** of small molecule new drugs approved by the FDA over the past five years, with a **27%** share of new drugs approved in 2025 [10] Industry Dynamics - **Challenges in Biotech**: - The industry faces long development cycles, high costs, and low success rates, leading to unmet clinical needs [2] - Biotech companies are under pressure to advance drug pipelines quickly to create value [2] - **Market Trends**: - There is a rebound in biotech funding, particularly benefiting early-stage businesses [39] - The demand for GLP-1 drugs is notably high, contributing to the company's financial performance [30] Operational Insights - **Capacity Utilization**: - The Tides business has seen significant capacity utilization, with plans to increase capacity further in 2026 [22][25] - The company is also expanding capabilities in oligonucleotides and small molecules alongside peptides [44] - **Quality Assurance**: - In 2025, the company completed **740 quality audits** with a 100% pass rate, reflecting its commitment to high standards [16][19] Future Outlook - **Guidance for 2026**: - The company anticipates that 2026 will at least match the performance of 2025, with official guidance to be provided on March 24, 2026 [31] - **Sustainability and ESG Initiatives**: - WuXi AppTec achieved the highest AAA rating from MSCI and improved its CDP Climate Change rating to A, reflecting its commitment to sustainability [15] Additional Considerations - **Investment in Talent and CapEx**: - The company plans to maintain a CapEx range of **5.5 billion to 6 billion RMB** in 2025, focusing on capabilities and talent retention [13][36] - **Impact of Currency Fluctuations**: - The company is monitoring the impact of RMB appreciation on its overseas business, with strategies in place to mitigate risks [33][35] This summary encapsulates the key points discussed during the WuXi AppTec FY Conference Call, highlighting the company's financial performance, operational strategies, and industry dynamics.